---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-320153"
form_type: "8-K/A"
ticker: "RVTY"
cik: "0000031791"
company_name: "REVVITY, INC."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:22:42.218970+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLegend FY2020 audited: revenue $241.9M, net income $90.6M

## Summary
- BioLegend net sales $241.9M, gross profit $169.7M, operating income $109.6M, net income $90.2M.
- Total assets $465.9M at Dec 31, 2020; cash $134.4M, short-term investments $90.0M.
- Pro forma combined financials for PerkinElmer and BioLegend for FY2020 and H1 2021 filed.
- Acquisition completed Sept 17, 2021 via merger of wholly owned subsidiaries.

## SEC filing metadata
- accession: 0001193125-21-320153
- form_type: 8-K/A
- ticker: RVTY
- cik: 0000031791
- company_name: REVVITY, INC.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/31791/000119312521320153/0001193125-21-320153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/31791/000119312521320153/d169075d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-320153
- JSON: https://secwatch.observer/filing/0001193125-21-320153.json
- Plain text: https://secwatch.observer/filing/0001193125-21-320153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.